ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on November 13, 2019. The filing serves to announce the company's financial results for the quarter ended September 30, 2019, via a press release furnished as Exhibit 99.1. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended September 30, 2019.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, specific management commentary, guidance, outlook, risks, or contingencies are not detailed in this document text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2019) for actual financial figures.
- Verify the specific revenue and net loss figures for the quarter ended September 30, 2019.
- Check the cash position and burn rate disclosed in the full press release.
- Confirm any updates to the company's product development pipeline or regulatory milestones mentioned in the press release.